Introduction
Most antitumor therapies including chemotherapy, g-irradiation or immunotherapy primarily act by inducing apoptosis in target cells (Herr and Debatin, 2001) . Apoptosis pathways may be initiated through different entry sites, such as death receptors (receptor pathway) or mitochondria (mitochondrial pathway) resulting in activation of effector caspases (Hengartner, 2000) . The latter pathway plays a crucial role in drug-induced apoptosis . Upon induction of apoptosis, apoptogenic factors such as cytochrome c, apoptosis-inducing factor (AIF) or second mitochondria-derived activator of caspase (Smac)/DIABLO are released from mitochondria into the cytosol (van Loo et al., 2002) . Cytochrome c triggers caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex, while Smac/DIA-BLO promotes caspase activation by neutralizing the inhibitory effects of inhibitor of apoptosis proteins (IAPs) (van Loo et al., 2002) . Defects in apoptosis programs, for example, loss or inactivation of proapoptotic molecules and/or aberrant activation of survival pathways, may cause drug resistance (Herr and Debatin, 2001; Johnstone et al., 2002) .
The transcription factor nuclear factor-kappaB (NFkB) has been connected to multiple aspects of oncogenesis, including inhibition of apoptosis by increasing the expression of survival factors (Karin et al., 2002) . NFkB is composed of hetero-or homodimers of the NFkB/Rel family of proteins (Karin et al., 2002) . In most cell types, NF-kB complexes are sequestered in the cytoplasm by their interaction with inhibitor of kB (IkB) proteins and therefore remain inactive (Karin et al., 2002) . NF-kB activity is induced in response to a variety of stimuli, for example, inflammatory cytokines, cellular stress, reactive oxygen species or anticancer agents. Most stimuli cause activation of IkB kinase (IKK) complexes which phosphorylate IkB proteins, triggering their degradation via the proteasome. Thereby NF-kB complexes are released to translocate into the nucleus, where they bind to specific DNA-binding sites and regulate the transcription of target genes (Hayden and Ghosh, 2004) . NF-kB target genes include various antiapoptotic proteins (Karin et al., 2002) , but also several proapoptotic molecules, consistent with reports that NF-kB can promote apoptosis under certain circumstances (Baetu et al., 2001; Ravi et al., 2001) . NF-kB is constitutively active in some cancers such as Hodgkin's lymphoma or pancreatic carcinoma, where it has been implicated in conferring chemoresistance (Algul et al., 2002; Younes et al., 2003) . Inhibition of NF-kB signaling, for example, by proteasome inhibitors, that prevent IkB-a degradation, or by overexpression of nondegradable IkB-a mutants has been reported to sensitize tumor cells to apoptosis induced by TNFa or anticancer agents (Jeremias et al., 1998; Karin et al., 2004) .
Betulinic acid (BetA) is a naturally occurring pentacyclic triterpenoid derived from white birch trees, which has been shown to induce apoptosis in a variety of tumor cells (Pisha et al., 1995; Fulda et al., 1997 Fulda et al., , 1999 Zuco et al., 2002) We previously described that BetAinduced apoptosis differs from that induced by anticancer agents such as doxorubicin, since BetA-induced apoptosis is not associated with the activation of ligand/ receptor systems, such as CD95, and does not involve p53 (Fulda et al., 1997) . In BetA-induced apoptosis, perturbation of mitochondrial function, e.g. loss of mitochondrial permeability transition and production of reactive oxygen species, precedes other key features of apoptosis, such as activation of the caspase cascade and nuclear fragmentation (Fulda et al., 1997 (Fulda et al., , 1998a . BetA triggers the production of reactive oxygen species (Fulda et al., 1998a) , which can also activate signaling cascades involving NF-kB (Zhang and Chen, 2004) . We recently found that BetA-induced apoptosis can be significantly enhanced in combination protocols, for example, together with the cytotoxic ligand TNF-related apoptosis-inducing ligand (TRAIL) (Fulda et al., 2004) . In search for novel strategies to augment the antitumor activity of BetA, we investigated the effect of BetA on NF-kB in the present study, since NF-kB is a mediator of cellular stress-induced apoptosis resistance (Zhang and Chen, 2004) . We found that BetA activates NF-kB, which, unexpectedly, promotes BetA-induced apoptosis in a cell type-specific manner.
Results

Activation of NF-kB by BetA
Since cellular stress, for example, triggered by chemotherapeutic agents, is known to activate the transcription factor NF-kB, we asked whether or not BetA induces NF-kB activation. To address this question, we selected SH-EP neuroblastoma cells, which have been previously proven to be suitable for studies on apoptosis pathways by our group and by other investigators (Fulda et al., 1997; Kim and Feldman, 2002) . We analyzed DNA-binding activity of NF-kB by electrophoretic mobility shift assay (EMSA) in nuclear extracts of SH-EP neuroblastoma cells treated with BetA, which are sensitive to BetA-induced apoptosis. Treatment with BetA resulted in a dose-dependent increase of NF-kB DNA binding (Figure 1a) . Kinetic analysis showed a relatively slow induction of NF-kB by BetA, which set in after 4-6 h stimulation (Figure 1b) . In contrast to BetA, TNFa stimulated full NF-kB activation already after 0.5 h (Figure 1b) . To analyze the composition of NF-kB DNA-binding complexes we performed EMSA supershift experiments. Antibodies recognizing p65 and p50 subunits, but not cRel-specific antibodies, caused a supershift of DNA-binding NF-kB complexes in nuclear extracts of BetA-or TNFa-treated SH-EP neuroblastoma cells (Figure 1c ), indicating that NF-kB complexes induced by BetA and TNFa mainly consisted of p65 and p50 subunits. Since, p65 was found to be part of the NFkB complexes induced by BetA, we also investigated nuclear translocation of p65 by fluorescence microscopy. Nuclear translocation of p65 was induced by BetA in SH-EP neuroblastoma cells and also by TNFa (Figure 1d ). To test whether NF-kB DNA-binding activity induced by BetA correlates to transcriptional activity, we performed dual luciferase assays of cells transfected with a reporter gene construct for NF-kB. BetA induced transcription of this artificial luciferase construct containing 3 Â kB binding sites to a similar extent as TNFa (Figure 1e ).
To exclude that activation of NF-kB by BetA is restricted to a particular cell line, we extended our studies to additional tumor cell lines. BetA induced DNA binding of NF-kB in SH-SY5Y neuroblastoma cells and LN229 glioblastoma cells as assessed by EMSA (Figure 2a and b) . NF-kB complexes induced by BetA mainly consisted of p65 and p50 subunits in both cell lines (Figure 2c and d) , similar to SH-EP neuroblastoma cells (Figure 1c) . Also, BetA enhanced NF-kB transcriptional activity in SH-SY5Y neuroblastoma and LN229 glioblastoma cells ( Figure 2e and f) ; however, not as strong as in SH-EP neuroblastoma cells (Figure 1e ). Activation of NF-kB after BetA treatment was also observed by EMSA in U373 glioblastoma cells and MeWo melanoma cells (data not shown). Together, these experiments demonstrate that BetA triggers NFkB activation in different tumor cell types.
NF-kB activation by BetA involves the IKK complex and degradation of IkB-a
We then selected SH-EP neuroblastoma cells to further elucidate the role of NF-kB in BetA-induced cell death. To investigate whether NF-kB activation by BetA involves the IKK complex, we performed IKK kinase assays. Treatment with BetA resulted in a timedependent increase in phosphorylation of IkB-a-(1-62)-gluthathione-S-transferase (GST), which was used as substrate for IKKs in kinase assays (Figure 3a) . Treatment with TNFa served as positive control to stimulate IKK-activity (Figure 3a) . According to the increased IKK-activity found in kinase assays (Figure 3a) , treatment with BetA also led to phosphorylation of IkB-a at serine 32/36 as detected by Western blot analysis, followed by degradation of IkB-a (Figure 3b) . In comparison to NF-kB induction by TNFa, IKKactivation as well as phosphorylation and degradation of IkB-a induced by BetA was less pronounced and occurred with delayed kinetics (Figure 3a and b) . This delayed timing of phosphorylation and degradation of IkB-a upon treatment with BetA corresponded to the delayed kinetic of NF-kB DNA-binding induced by 
NF-kB activation and apoptosis induction by BetA
To investigate the relation of NF-kB activation with apoptosis induction by BetA, we generated SH-EP neuroblastoma cells stable transfected with a 3 Â kBluciferase reporter vector and performed a kinetic analysis of NF-kB transcriptional activity and apoptosis induction following treatment with BetA. NF-kB transcriptional activity preceded apoptosis upon treatment with BetA and markedly decreased upon induction of apoptosis ( Figure 4 ). Interestingly, inhibition of apoptosis by the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) resulted in prolonged and increased transcriptional activity of NF-kB induced by BetA (Figure 4 ). Similar results were obtained in two other clones of 3 Â kBreporter gene transfected SH-EP cells (data not shown). These findings indicate that NF-kB activation by BetA occurs before apoptosis induction and is terminated by apoptotic processes. 
NF-kB inhibition by chemical inhibitors attenuates BetA-induced apoptosis
Since NF-kB may inhibit or promote apoptosis, for example, depending on the stimulus applied, we next investigated the functional impact of NF-kB activation by BetA. To block NF-kB activation SH-EP neuroblastoma cells were treated with different chemical inhibitors of NF-kB prior to treatment with BetA, including the proteasome inhibitor MG132, the antioxidant pyrrolidine dithiocarbamate (PDTC) and the IKK inhibitor sulfasalazine (Wahl et al., 1998) . Pretreatment with NF-kB inhibitors markedly reduced NF-kB activation by BetA (Figure 5a) . Surprisingly, we found that pretreatment with NF-kB inhibitors significantly attenuated BetA-induced apoptosis (Figure 5b ). Although individual NF-kB inhibitors varied in their ability to inhibit NF-kB DNA-binding activity as determined by EMSA, they all reduced BetA-induced apoptosis to a similar extent, which may be due to the lack of absolute specificity of these compounds. In contrast, TNFa-induced apoptosis was significantly enhanced by pretreatment with MG132 or sulfasalazine ( Figure 5b ). Thus, these results point to a proapoptotic role of NF-kB induced by BetA.
Specific inhibition of NF-kB attenuates apoptosis in a cell type-specific manner
Since chemical inhibitors of NF-kB may affect apoptosis via unspecific effects independent of NF-kB inhibition, we aimed to specifically block NF-kB activation to elucidate the role of NF-kB in BetA-induced apoptosis.
To this end, we engineered SH-EP neuroblastoma cells to stable express an IkB-a superrepressor mutant, IkB-a-S(32,36)A, which cannot be phosphorylated at the phosphorylation sites serines 32/36. Levels of ectopically expressed IkB-a mutant was controlled by Western blot analysis ( Figure 6a ) and its inhibition of BetA or TNFainduced NF-kB activity was shown by EMSA ( Figure 6b ). Importantly, BetA-induced apoptosis was significantly reduced in SH-EP neuroblastoma cells stable expressing IkB-a superrepressor compared to vector control cells (Figure 6c-e) . In contrast, specific inhibition of NF-kB significantly enhanced apoptosis following stimulation with TNFa (Figure 6c-e) . In addition to persistent NF-kB inhibition in cells stable transfected with IkB-a super-repressor, we also used adenoviral transduction of IkB-a super-repressor mutant to transiently block NF-kB activation. Adenoviral transduction of SH-EP neuroblastoma cells reached 80-90% transduction efficiency, which was controlled by flow cytometry (Figure 7a) . Accordingly, adenoviral transduction resulted in high ectopic expression of IkB-a-S(32,36)A super-repressor protein as visualized by Western blot analysis (Figure 7b ), which completely blocked NF-kB induction by BetA or TNFa in SH-EP neuroblastoma cells (Figure 7c ). Importantly, BetA-induced apoptosis was significantly reduced in IkB-a super-repressor-expressing SH-EP neuroblastoma cells compared to LacZ-expressing cells (Figure 8a and  b) . In contrast, TNFa-induced apoptosis was strongly increased by expression of IkB-a super-repressor in SH-EP neuroblastoma cells (Figure 8a and b) . As the adenoviral transduction of IkB-a super-repressor mutant turned out to be the most efficient strategy to inhibit NF-kB, we used this approach in LN229 glioblastoma and SH-SY5Y neuroblastoma cells to further elucidate the role of NF-kB in BetA-induced apoptosis. Similarly, we obtained 80-90% transduction efficiency and high ectopic expression of IkB-a-S(32,36)A in these cell lines (Figure 7a and b) . Accordingly, BetA-or TNFa-induced NF-kB activation was completely blocked in LN229 glioblastoma and SH-SY5Y neuroblastoma cells overexpressing the IkB-a super-repressor (Figure 7d and e) . However, no difference in BetA-induced apoptosis was observed in SH-SY5Y neuroblastoma or LN229 glioblastoma cells transduced with LacZ-or IkB-a-S(32,36)A-carrying adenovirus, whereas TNFa-induced apoptosis was strongly increased in LN229 glioblastoma cells expressing IkB-a super-repressor (Figure 8c and d) . TNFa could not be used as positive control in SH-SY5Y neuroblastoma cells as these cells do not express caspase-8 and are resistant to death receptor-mediated apoptosis (Fulda and Debatin, 2002 ). These results demonstrate that NF-kB activation by BetA promoted apoptosis in SH-EP neuroblastoma cells, whereas it had no effect on apoptosis in two other investigated cell lines. The fact that complete inhibition of NF-kB DNA-binding activity by adenoviral gene transfer of dominant-negative IkB-super-repressor significantly reduced, but did not completely abolish BetA-induced apoptosis indicates that additional mechanisms besides NF-kB are involved in mediating BetA-induced apoptosis. Notably, in contrast to the antiapoptotic activity of NF-kB upon stimulation with TNFa, we found no evidence for an antiapoptotic function of NF-kB induced by BetA. 
Discussion
The transcription factor NF-kB is a key mediator of the cellular stress response, for example, upon anticancer therapy, which typically engages survival pathways (Karin et al., 2002; Zhang and Chen, 2004) . BetA, a natural compound derived from white birch trees, induces apoptosis in various tumor cells (Fulda et al., 1997 (Fulda et al., , 1998a . We recently demonstrated that combination regimens with BetA, for example, a combination of BetA and the cytotoxic ligand TRAIL, significantly enhanced BetA-induced apoptosis (Fulda et al., 2004) . Also, BetA was reported to act in concert with ionizing radiation or anticancer agents (Selzer et al., 2000; Sawada et al., 2004) . In search for novel approaches to augment the therapeutic efficacy Induction of NF-kB by BetA was mediated by an increase in IKK activity and enhanced phosphorylation of IkB-a at serine 32/36 preceding its degradation. This was accompanied by translocation of the NF-kB subunit p65 from the cytosol into the nucleus and enhanced NF-kB DNA binding, followed by an increase in NF-kB transcriptional activity. Supershift analysis revealed that NF-kB DNA-binding complexes induced by BetA or TNFa consisted of p65/p50 heterodimers. Thus, BetA-induced NF-kB activation involved signaling components of the canonical NF-kB pathway, similar to those activated by the typical NF-kB inducer TNFa. However, the kinetics of NF-kB activation by BetA and TNF-alpha markedly differed: While NF-kB activation by BetA occurred within hours, TNFa rapidly activated NF-kB within minutes. The kinetic of NF-kB activation by BetA resembled that of so called atypical NF-kB activators, for example, UV irradiation, chemotherapeutic drugs and ionizing radiation, which induce DNA binding of NF-kB with relatively slow kinetics, peaking at about 4 h after activation (Hayden and Ghosh, 2004) . For atypical NF-kB activators, both IKK-dependent and independent mechanisms of NF-kB activation have been proposed (Hayden and Ghosh, 2004) . Thus, BetA can be classified as atypical NF-kB inducer, which triggers NF-kB activation in an IKKdependent manner. Atypical NF-kB activators may cause production of reactive oxygen species, which are discussed to be responsible for NF-kB activation (Hayden and Ghosh, 2004) . BetA also induces production of reactive oxygen species (Fulda et al., 1998a) , which can be an upstream signal for BetA-mediated NF-kB induction (Zhang and Chen, 2004) . In line with this notion, we found that BetA-induced NF-kB activation and apoptosis was significantly reduced in the presence of the antioxidant PDTC. Previously, BetA has been reported to inhibit NF-kB activation and NFkB-regulated gene expression induced by proinflammatory cytokines and carcinogens (Takada and Aggarwal, 2003) . To exclude the possibility that NF-kB activation by BetA is restricted to the BetA preparation used in our studies, we tested various BetA preparations of different suppliers, including the one described by Takada and Aggarwal, and observed similarly activities in terms of NF-kB induction (data not shown). These findings suggest that cell type-specific differences in regulation of NF-kB by BetA may exist. Importantly, using different experimental approaches to block NF-kB activation, including chemical inhibitors as well as stable or transient-specific inhibition of NF-kB, we demonstrate that NF-kB activation by BetA significantly enhanced BetA-triggered apoptosis in SH-EP neuroblastoma cells. Inhibition of NF-kB had no impact on BetA-induced apoptosis in two other cell lines, indicating that NF-kB promotes apoptosis in a cell type-dependent manner. This differential apoptosis response to inhibition of NF-kB upon treament with BetA might be related to the degree of NF-kB transcriptional activation by BetA, which was most pronounced in SH-EP neuroblastoma cells compared to the other two cell lines. In addition, the composition of pro-and antiapoptotic molecules may differ between the cell lines setting the threshold for apoptosis induction by BetA. In line with this notion, SH-EP neuroblastoma cells proved to be more sensitive to BetA-induced apoptosis compared to SH-SY5Y neuroblastoma and LN-229 glioblastoma cells. Remarkably, we found no evidence for an antiapoptotic function of NF-kB upon treatment with BetA in the cell lines studied, in sharp contrast to the proinflammatory cytokine TNFa under the same experimental conditions. Although a large number of studies has led to the general perception that NF-kB mediates resistance to programmed cell death through induction of antiapoptotic genes, there are also reports demonstrating that under certain circumstances the opposite may occur (Karin et al., 2002; Hayden and Ghosh, 2004) . In particular, many atypical inducers of NF-kB, for example, UV irradiation, hydrogen peroxide and some anticancer drugs, have been associated with a proapoptotic function of NF-kB (Hayden and Ghosh, 2004) . Accordingly, promoter activation of certain proapoptotic molecules has been shown to be under the control of NF-kB (Baetu et al., 2001; Ravi et al., 2001) . Also, p65 has recently been reported to promote apoptosis by actively repressing transcription of antiapoptotic genes through association of p65 with histone deacetylase-containing complexes, acting as corepressor (Campbell et al., 2004) . The mechanisms underlying the proapoptotic function of NF-kB during BetA-induced apoptosis remain to be elucidated in future studies.
Clinically, resistance to apoptosis is a major cause of primary or acquired nonresponsiveness of cancers to cytotoxic treatment. To overcome resistance, combination protocols may prove to be advantageous in malignancies that still partially respond to treatment approaches. Recent evidence demonstrates that the cytotoxic activity of BetA can be markedly enhanced both in vitro and in vivo in combination protocols, for example, together with chemotherapy, ionizing radiation or TRAIL (Selzer et al., 2000; Fulda et al., 2004; Sawada et al., 2004) . Thus, the potential of BetA for anticancer therapy may particularly reside in combination protocols in order to achieve maximal antitumor activity. Based on the concept that many cytotoxic approaches used in cancer treatment simultaneously activate cell death programs as well as survival pathways such as NF-kB, small molecule inhibitors of NF-kB have been implemented into treatment protocols to enhance treatment response (Weaver et al., 2003; Karin et al., 2004) . Importantly, our findings demonstrate a proapoptotic role of NF-kB upon activation by BetA in certain cell types without any evidence for an antiapoptotic function of NF-kB induced by BetA. This indicates that NF-kB inhibitors in combination with BetA would have no therapeutic benefit or could even be contraproductive in certain tumors. Thus, our findings have important implications for the design of BetAbased combination regimens.
Materials and methods
Cell culture and material SH-EP neuroblastoma cells were maintained in RPMI 1640 (Life Technologies Inc., Eggenstein, Germany), LN229 and U373 glioblastoma cells, SH-SY5Y neuroblastoma cells and MeWo melanoma cells were maintained in DMEM (Life Technologies Inc.), supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin (Biochrom, Berlin, Germany), 100 mg/ml streptomycin (Biochrom), 10 mM HEPES (Biochrom) and 2 mM L-glutamine (Biochrom). Cells were cultured in 75 or 150 cm 2 flasks (Falcon, Heidelberg, Germany) and seeded in 10 cm dishes (2-3 Â 10 6 cells), 12-well plates (1 Â 10 5 cells) or 24-well plates (0.5 Â 10 5 cells) for experiments. All chemicals were obtained from Sigma (Steinheim, Germany) unless otherwise indicated. BetA with a purity >99% was purchased from BioService Halle (Halle, Germany). A stock solution of 4 mg/ml BetA in DMSO was prepared and stored at À201C, thawed for use, prediluted in DMSO and filled up with medium to a resulting DMSO concentration of 0.5%, which was also used for DMSO controls. TNFa was purchased from Biochrom, MG132 from Calbiochem (Schwalbach, Germany), PDTC and sulfasalazine from Sigma.
Transfection SH-EP neuroblastoma cells were transfected with pcDNA3 empty vectors or pcDNA3-containing IkB-a-S(32,36)A and selected with 1 mg/ml G418 (Life Technologies) to obtain a bulk culture stable expressing IkB-a-S(32,36)A. SH-EP neuroblastoma cell clones containing luciferase reporter gene vectors with 3 Â kB binding sites (Baumann et al., 2002) were obtained by cotransfection with a pSV-puro vector and selection with 1 mg/ml puromycin.
Nuclear protein extraction and electrophoretic mobility shift assay Adherent cells were collected from 10 cm dishes by scraping and centrifugation (1000 g for 5 min at 41C). After washing once with ice cold PBS, cell pellets were resuspended in 200 ml low salt buffer (10 mM HEPES-OH pH 7.9; 1.5 mM MgCl 2 ; 10 mM KCl) and incubated for 10 min on ice. After addition of 20 ml of a 10% NP-40 solution, samples were mixed vigorously for 30 s. Nuclei were collected by centrifugation and resuspended in 50 ml high salt buffer (20 mM HEPES-OH pH 7.9; 420 mM NaCl; 1.5 mM MgCl 2 ; 0.2 mM EDTA; 25% glycerol). Both buffers were supplemented with a protease-inhibitor cocktail (Sigma); 0.2 mM PMSF; 0.5 mM DTT and 1 mM sodium-ortho-vanadate before use. Nuclei were incubated 15 min on ice and vortexed periodically. Nuclear extracts were obtained by centrifugation at 12 500 Â g for 10 min at 41C and stored at À801C. Protein concentration was determined with the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) according to manufacture's instruction. NF-kB-specific oligonucleotides 5 0 -AGTTGAGGGGACTTTCCCAGGC (sense), 5 0 -GCCTGGGAAAGTCCCCTCAACT (antisense) and Sp1-specific oligonucleotides 5 0 -ATTCGATCGGGGCGGGGCG AG (sense) and 5 0 -GCTCGCCCCGCCCCGATCGAA (antisense) were used for EMSA. Single-stranded oligonucleotides were labeled with g-32 P-ATP (Amersham, Freiburg, Germany) by T4-polynucleotide kinase (MBI Fermentas, St Leon-Rot, Germany). A twofold molar excess of unlabeled complementary oligonucleotides was annealed and double-stranded oligonucleotides were purified on spin columns (Micro BioSpin P30, BioRad, Mu¨nchen, Germany). Binding reactions were performed for 30 min on ice in 20 ml buffer (1 mM MgCl 2 ; 0.5 mM EDTA; 0.5 mM DTT; 50 mM NaCl; 10 mM Tris-HCl, pH 7.5; 4% glycerol) containing 5 mg nuclear extract protein, 1 mg poly(dI:dC) (Sigma) and 10 000 cpm labeled oligonucleotide. For supershift experiments 1 mg of c-Rel (sc-70X), p50 (sc-7178X) or p65 (sc-372X) rabbit polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were added to the binding reactions and incubated 1 h on ice before addition of labeled oligonucleotides. Binding complexes were resolved by electrophoresis in vertical nondenaturing 6% polyacrylamide gels, using 0.3 Â TBE as running buffer. Gels 
